Differential effects of antipsychotics on hippocampal presynaptic protein expressions and recognition memory in a schizophrenia model in mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 39, Issue 1, 2012, Pages 62-68

  Ozdemir, H ^a   Ertugrul, A ^a   Basar, K ^a   Saka, E ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Clozapine; Schizophrenia; SNAP 25; Synaptic plasticity; Synaptophysin

Indexed keywords

CLOZAPINE; DIZOCILPINE; HALOPERIDOL; SYNAPTOPHYSIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG EFFICACY; ELECTROENCEPHALOGRAM; FRONTAL CORTEX; HIPPOCAMPUS; LOCOMOTION; MALE; MEMORY; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECOGNITION; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; FRONTAL LOBE; HALOPERIDOL; HIPPOCAMPUS; MALE; MICE; MOTOR ACTIVITY; PRESYNAPTIC TERMINALS; RECOGNITION (PSYCHOLOGY); SCHIZOPHRENIA; SYNAPTOPHYSIN; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25;

EID: 84864507885     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.05.009     Document Type: Article

References (65)

1. Bai O., Chlan-Fourney J., Bowen R., Keegan D., Li X.M. Expression of BDNF mRNA in rat hippocampus after treatmnet with antipsychotic drugs. J Neurosci Res 2003, 71(1):127-131. [Jan 1].
2. Barr A.M., Young C.E., Phillips A.G., Honer W.G. Selective effects of typical antipsychotic drugs on SNAP-25 and synaptophysin in the hippocampal trisynaptic pathway. Int J Neuropsychopharmacol 2006, 9(4):457-463. [Aug].
3. Beraki S., Kuzmin A., Tai F., Ogren S.O. Repeated low dose of phencyclidine administration impairs spatial learning in mice: blockade by clozapine but not by haloperidol. Eur Neuropsychopharmacol 2008, 18(7):486-497. [Jul].
4. Bragina L., Melone M., Fattorini G., Torres-Ramos M., Vallejo-Illarramendi A., Matute C. GLT-1 down-regulation induced by clozapine in rat frontal cortex is associated with synaptophysin up-regulation. J Neurochem 2006, 99(1):134-141. [Oct].
5. Briand L.A., Flagel S.B., Garcia-Fuster M.J., Watson S.J., Akil H., Sarter M., et al. Persistent alterations in cognitive function and prefrontal dopamine D2 receptors following extended, but not limited, access to self-administered cocaine. Neuropsychopharmacology 2008, 33(12):2969-2980. [2008 Nov].
6. Castillo-Gómez E., Gómez-Climent M.A., Varea E., Guirado R., Blasco-Ibáñez J.M., Crespo C., et al. Dopamine acting through D2 receptors modulates the expression of PSA-NCAM, a molecule related to neuronal structural plasticity, in the medial prefrontal cortex of adult rats. Exp Neurol 2008, 214(1):97-111. [Nov].
7. Chlan-Fourney J., Ashe P., Nylen K., Juorio A.V., Li X.M. Differential regulation of hippocampal BDNFmRNAby typical and atypical antipsychotic administration. Brain Res 2002, 954(1):11-20. [Nov 1].
8. Critchlow H.M., Maycox P.R., Skepper J.N., Krylova O. Clozapine and haloperidol differentially regulate dendritic spine formation and synaptogenesis in rat hippocampal neurons. Mol Cell Neurosci 2006, 32(4):356-365. [Aug].
9. Dawirs R.R., Hildebrandt K., Teuchert-Noodt G. Adult treatment with haloperidol increases dentate granule cell proliferation in the gerbil hippocampus. J Neural Transm 1998, 105(2-3):317-327.
10. Didriksen M., Kreilgaard M., Arnt J. Sertindole, in contrast to clozapine and olanzapine, does not disrupt water maze performance after acute or chronic treatment. Eur J Pharmacol 2006, 542(1-3):108-115. [Aug 7].
11. Eastwood S.L. The synaptic pathology of schizophrenia: is aberrant neurodevelopment and plasticity to blame?. Int Rev Neurobiol 2004, 59:47-72.
12. Eastwood S.L., Harrison P.J. Detection and quantification of hippocampal synaptophysin messenger RNA in schizophrenia using autoclaved, formalin-fixed, paraffin wax-embedded sections. Neuroscience 1999, 93(1):99-106.
13. Eastwood S.L., Burnet P.W., Harrison P.J. Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia S.L. Neuroscience 1995, 66(2):309-319. [May].
14. Eastwood S.L., Heffernan J., Harrison P.J. Chronic haloperidol treatment differentially affects the expression of synaptic and neuronal plasticity-associated genes. Mol Psychiatry 1997, (4):322-329. [Jul 2].
15. Eastwood S.L., Burnet P.W., Harrison P.J. Expression of complexin I and II mRNAs and their regulation by antipsychotic drugs in the rat forebrain. Synapse 2000, 36:167-177.
16. Eastwood S.L., Cairns N.J., Harrison P.J. Synaptophysin gene expression in schizophrenia. Investigation of synaptic pathology in the cerebral cortex. Br J Psychiatry 2000, 176:236-242. [Mar].
17. Ertuǧrul A., Ozdemir H., Vural A., Dalkara T., Meltzer H.Y., Saka E. The influence of N-desmethylclozapine and clozapine on recognition memory and BDNF expression in hippocampus. Brain Res Bull 2011, 84(2):144-150. [Feb 1].
18. Fatemi S.H., Earle J.A., Stary J.M., Lee S., Sedgewick J. Altered levels of the synaptosomal associated protein SNAP-25 in hippocampus of subjects with mood disorders and schizophrenia. Neuroreport 2001, 12(15):3257-3262. [Oct 29].
19. Fattorini G., Bragina L., Candiracci C., Melone M., Conti F., Cozzi A., et al. Acute phencyclidine administration reduces extracellular glutamate levels and the expression of synaptophysin and SNAP-25 in rat frontal cortex. Schizophr Res 2009, 108(1-3):288-289.
20. Gabriel S.M., Haroutunian V., Powchik P., Honer W.G., Davidson M., Davies P., et al. Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia. Arch Gen Psychiatry 1997, 54(6):559-566. [Jun].
21. Glantz L.A., Lewis D.A. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity. Arch Gen Psychiatry 1997, 54(7):660-669.
22. Gray L., van den Buuse M., Scarr E., Dean B., Hannan A.J. Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-d-aspartic acid receptor up-regulation. Int J Neuropsychopharmacol 2009, 12(1):45-60. [Feb].
23. Grayson B., Idris N.F., Neill J.C. Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav Brain Res 2007, 184(1):31-38. [Nov 22].
24. Halim N.D., Weickert C.S., McClintock B.W., Hyde T.M., Weinberger D.R., Kleinman J.E., et al. Presynaptic proteins in the prefrontal cortex of patients with schizophrenia and rats with abnormal prefrontal development. Mol Psychiatry 2003, 8(9):797-810.
25. Halim N.D., Weickert C.S., McClintock B.W., Weinberger D.R., Lipska B.K. Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus. Neuropsychopharmacology 2004, (6):1063-1069. [Jun 29].
26. Harris L.W., Sharp T., Gartlon J., Jones D.N., Harrison P.J. Long-term behavioural, molecular and morphological effects of neonatal NMDA receptor antagonism. Eur J Neurosci 2003, 18(6):1706-1710.
27. Harrison P.J., Eastwood S.L. Neuropathological studies of synaptic connectivity in the hippocampal formation in schizophrenia. Hippocampus 2001, 11(5):508-519.
28. Hashimoto K., Fujita Y., Shimizu E., Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. Eur J Pharmacol 2005, 519(1-2):114-117. [Sep 5].
29. Holahan M.R., Rekart J.L., Sandoval J., Routtenberg A. Spatial learning induces presynaptic structural remodeling in the hippocampal mossy fiber system of two rat strains. Hippocampus 2006, 16(6):560-570.
30. Homayoun H., Moghaddam B. Fine tuning of awake prefrontal cortex neurons by clozapine: comparison with haloperidol and N-desmethylclozapine. Biol Psychiatry 2007, 61(5):679-685. [Mar 1].
31. Hou Q., Gao X., Zhang X., Kong L., Wang X., Bian W. SNAP-25 in hippocampal CA1 region is involved in memory consolidation. Eur J Neurosci 2004, 20(6):1593-1603. [Sep].
32. Jeans A.F., Oliver P.L., Johnson R., Capogna M., Vikman J., Molnár Z., et al. A dominant mutation in Snap25 causes impaired vesicle trafficking, sensorimotor gating, and ataxia in the blind-drunk mouse. Proc Natl Acad Sci USA 2007, 104(7):2431-2436.
33. Jentsch J.D., Taylor J.R., Roth R.H. Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion. Neuropsychopharmacology 1998, 19(2):105-113. [Aug].
34. Konradi C., Heckers S. Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biol Psychiatry 2001, 50:729-742. [Nov].
35. Lewis C.M., Levinson D.F., Wise L.H., DeLisi L.E., Straub R.E., Hovatta I., et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. Am J Hum Genet 2003, 73(1):34-48.
36. Li Z., Huang M., Ichikawa J., Dai J., Meltzer H.Y. N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors. Neuropsychopharmacology 2005, 30(11):1986-1995. [Nov].
37. Linden A.M., Vaisanen J., Lakso M., Nawa H., Wong G., Castren E. Expression of neurotrophins BDNF and NT-3, and their receptors in rat brain after administration of antipsychotic and psychotrophic agents. J Mol Neurosci 2000, 14(1-2):27-37. [Feb-Apr].
38. Lipska B.K., Khaing Z.Z., Weickert C.S., Weinberger D.R. BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipschotic drugs. Eur J Neurosci 2001, 14(1):135-144. [Jul].
39. MacDonald M.L., Eaton M.E., Dudman J.T., Konradi C. Antipsychotic drugs elevate mRNA levels of presynaptic proteins in the frontal cortex of the rat. Biol Psychiatry 2005, 57(9):1041-1051. [May].
40. Maeda K., Sugino H., Hirose T., Kitagawa H., Nagai T., Mizoguchi H., et al. Clozapine prevents a decrease in neurogenesis in mice repeatedly treated with phencyclidine. J Pharmacol Sci 2007, 103(3):299-308. [Mar].
41. Malberg J.E., Eisch A.J., Nestler E.J., Duman R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000, 20(24):9104-9110. [Dec 15].
42. Mehta P.P., Battenberg E., Wilson M.C. SNAP-25 and synaptotagmin involvement in the final Ca(2+)-dependent triggering of neurotransmitter exocytosis. Proc Natl Acad Sci USA 1996, 93(19):10471-10476. [Sep 17].
43. Morihara T., Mizoguchi A., Takahashi M., Kozaki S., Tsujihara T., Kawano S., et al. Distribution of synaptosomal-associated protein 25 in nerve growth cones and reduction of neurite outgrowth by botulinum neurotoxin A without altering growth cone morphology in dorsal root ganglion neurons and PC-12 cells. Neuroscience 1999, 91(2):695-706.
44. Mouri A., Noda Y., Enomoto T., Nabeshima T. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem Int 2007, 51(2-4):173-184. [Jul-Sep].
45. Müller D.J., Klempan T.A., De Luca V., Sicard T., Volavka J., Czobor P., et al. The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neurosci Lett 2005, 379(2):81-89.
46. Nakahara T., Nakamura K., Tsutsumi T., Hashimoto K., Hondo H., Hisatomi S., et al. Effect of chronic haloperidol treatment on synaptic protein mRNAs in the rat brain. Brain Res Mol Brain Res 1998, 61(1-2):238-242. [Oct 30].
47. Osen-Sand A., Catsicas M., Staple J.K., Jones K.A., Ayala G., Knowles J., et al. Inhibition of axonal growth by SNAP-25 antisense oligonucleotides in vitro and in vivo. Nature 1993, 364(6436):445-448. [Jul 29].
48. Owen M.J., O'Donovan M.C., Harrison P.J. Schizophrenia: a genetic disorder of the synapse. BMJ 2005, 330(7484):158-159. [Jan 22].
49. Pillai-Nair N., Panicker A.K., Rodriguiz R.M., Gilmore K.L., Demyanenko G.P., Huang J.Z. Neural cell adhesion molecule-secreting transgenic mice display abnormalities in GABAergic interneurons and alterations in behavior. J Neurosci 2005, 25(18):4659-4671.
50. Pletnikov M.V., Ayhan Y., Nikolskaia O., Xu Y., Ovanesov M.V., Huang H. Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia. Mol Psychiatry 2008, 13(2):173-186.
51. Rajji T.K., Uchida H., Ismail Z., Ng W., Mamo D.C., Remington G. Clozapine and global cognition in schizophrenia. J Clin Psychopharmacol 2010, 30(4):431-436. [Aug].
52. Sawada K., Young C.E., Barr A.M., Longworth K., Takahashi S., Arango V., et al. Altered immunoreactivity of complexin protein in prefrontal cortex in severe mental illness. Mol Psychiatry 2002, 7(5):484-492.
53. Schmitt A., Weber S., Jatzko A., Braus D.F., Henn F.A. Hippocampal volume and cell proliferation after acute and chronic clozapine or haloperidol treatment. J Neural Transm 2004, 111(1):91-100. [Jan].
54. Schmitt U., Tanimoto N., Seeliger M., Schaeffel F., Leube R.E. Detection of behavioral alterations and learning deficits in mice lacking synaptophysin. Neuroscience 2009, 162(2):234-243. [Aug 18].
55. Schröder N., de Lima M.N., Quevedo J., Dal Pizzol F., Roesler R. Impairing effects of chronic haloperidol and clozapine treatment on recognition memory: possible relation to oxidative stress. Schizophr Res 2005, 73(2-3):377-378. [Mar 1].
56. Spellmann I., Müller N., Musil R., Zill P., Douhet A., Dehning S., et al. Associations of SNAP-25 polymorphisms with cognitive dysfunctions in Caucasian patients with schizophrenia during a brief trail of treatment with atypical antipsychotics. Eur Arch Psychiatry Clin Neurosci 2008, 258(6):335-344. [Sep].
57. Sur C., Mallorga P.J., Wittmann M., Jacobson M.A., Pascarella D., Williams J.B., et al. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity. Proc Natl Acad Sci USA 2003, 100(23):13674-13679.
58. Thompson P.M., Sower A.C., Perrone-Bizzozero N.I. Altered levels of the synaptosomal associated protein SNAP-25 in schizophrenia. Biol Psychiatry 1998, 43(4):239-243. [Feb 15].
59. Thompson P.M., Egbufoama S., Vawter M.P. SNAP-25 reduction in the hippocampus of patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27(3):411-417. [May].
60. Thomsen M.S., Christensen D.Z., Hansen H.H., Redrobe J.P., Mikkelsen J.D. Alpha(7) nicotinic acetylcholine receptor activation prevents behavioral and molecular changes induced by repeated phencyclidine treatment. Neuropharmacology 2009, 56(6-7):1001-1009. [May-Jun].
61. Valtorta F., Pennuto M., Bonanomi D., Benfenati F. Synaptophysin: leading actor or walk-on role in synaptic vesicle exocytosis?. Bioessays 2004, 26(4):445-453. [Apr].
62. Varty G.B., Marsden C.A., Higgins G.A. Reduced synaptophysin immunoreactivity in the dentate gyrus of prepulse inhibition-impaired isolation-reared rats. Brain Res 1999, 824(2):197-203. [Apr 10].
63. Vawter M.P., Thatcher L., Usen N., Hyde T.M., Kleinman J.E., Freed W.J. Reduction of synapsin in the hippocampus of patients with bipolar disorder and schizophrenia. Mol Psychiatry 2002, 7(6):571-578.
64. Young J.W., Powell S.B., Risbrough V., Marston H.M., Geyer M.A. Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther 2009, 122(2):150-202. [May].
65. Zheng X., Bobich J.A. A sequential view of neurotransmitter release. Brain Res Bull 1998, 47(2):117-128. [Sep15].